Clinical development success rate in novel cardiovascular drugs U.S. 2008-2019
Between 2008 and 2019, around 50.9 percent of cardiovascular novel drugs in phase III continued to a New Drug Application (NDA) or a Biologic License Application (BLA). In total, only some six percent of cardiovascular novel drugs received approvals. This statistic illustrates the success rate of critical development in novel cardiovascular disease drugs in the United States from 2008 to 2019.